Wednesday, 20 April 2022

BioLargo Continues Growth Trend by Breaking Quarterly Revenue Record

Westminster, CA – April 20, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, today announced a company-wide quarterly revenue record for the first quarter of 2022. The company also announced it had been awarded the initial contract for a waste-to-energy conversion plant project.

New company-wide quarterly revenue record

BioLargo generated approximately $900,000 in revenue (company-wide) for the first quarter of 2022, representing an approximate 60% increase compared with the same period in 2021. Leading the way was subsidiary ONM Environmental with a new quarterly revenue record of approximately $550,000, and BioLargo’s engineering subsidiary with quarterly revenue of approximately $350,000, while it continued to support R&D on the company’s patented technologies. With these revenues, each of ONM Environmental and BioLargo Engineering moved closer to generating an operating profit. Note however, these preliminary revenue figures have not been reviewed, and are subject to change pending review by the company’s independent registered public accounting firm; the company will include its full results of operations in its quarterly report, which it intends to file with the SEC on about May 16, 2022.

Feasibility contract awarded for potential large waste-to-energy conversion plant project

BioLargo Engineering has been retained to conduct a feasibility study by a Southern California based sustainable energy services company intending to build a waste-to-energy conversion plant in South America. The site of the proposed conversion plant is approximately 296 acres, where it is planned to process over two million tons of municipal solid waste annually. A feasibility study is typically the first step in the design process for a new project of this size, and will address multiple fundamental factors that will influence the design and operation of the anticipated facility, including technology options, rough costs to construct and operate, environmental impacts, and rough equipment sizing. The feasibility study would then inform and facilitate the development of a design basis document, then conceptual design, and ultimately the front-end engineering design. Thus far, BioLargo’s engineers have been contracted on the feasibility study only, but expect to be involved in subsequent phases should the project move forward as planned.

BioLargo’s air quality control division (ONM Environmental), with a significant client base in the waste handling industry, was critical in bringing this project to the company and will work with BioLargo’s engineers to execute this project. ONM Environmental brings to the table a team with extensive expertise surrounding the design and operation of waste handling facilities, and BioLargo Engineering brings a team of veteran engineers with decades of experience designing and integrating complex projects as well as specific expertise in the area of waste-to-energy conversion.

Randall Moore, President of BioLargo Engineering, Science & Technologies, said, “The development of this waste-to-energy conversion plant is directly in our wheelhouse of past experience and knowledge. To process two million tons of municipal solid waste per year, the total capital outlay by the developer for a processing plant of that size could exceed $500 million, with the potential to keep our team busy for the next four years.”

Dennis P. Calvert, President and CEO of BioLargo, commented, “We look forward to sharing additional information as this project advances. We are continuing our strategy of employing strategic partnerships to develop new revenue channels for our cleantech products and services. As we referenced in our recently published annual report, we have additional channel partnerships in various stages of negotiation for our PFAS treatment system and are eager to provide more information soon. When combined with our other partnerships aimed at delivering cleantech solutions, including with Garratt-Callahan and Ikigai, we believe these record revenues are the beginning of what we believe will be accelerated growth for our company.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Monday, 4 April 2022

BioLargo Corporate Video

 "The vision for BioLargo is to be synonymous with clean air, clean water, clean Earth."

- Dennis Calvert, President and CEO of BioLargo.

Friday, 1 April 2022

BioLargo Annual Earnings Results Webcast and Conference Call Monday, April 4, 2022 - 4:30 PM Eastern Time

Westminster, CA – April 1, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, will host an investor webcast and conference call on Monday April 4, 2022, at 1:30 pm PT / 4:30 pm ET, open to the public. The event will be held to review the company’s year-end financial results, discuss recent commercial milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register, download, and install any necessary audio video software.

To participate in the live webcast and teleconference:

Webcast Linkhttps://www.webcaster4.com/Webcast/Page/2448/44944

Teleconference Domestic: 888-506-0062

Teleconference International: 973-528-0011

Participant Access Code: 546210

To watch or listen to a replay of the webcast or teleconference:

Webcast Replay Expiration: Tuesday, April 4, 2023

Teleconference Replay Expiration: Monday, April 18, 2022

Teleconference Replay Domestic: 877-481-4010

Teleconference Replay International: 919-882-2331

Replay Passcode: 44944

The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo’s website at biolargo.com/investor-relations


About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com

Contact Information

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.


Thursday, 31 March 2022

BioLargo Annual Report for 2021 Highlights Active Commercial Catalysts, Expanding Partnerships, and Improved Balance Sheet














Westminster, CA – March 31, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Annual Report on Form 10-K with the SEC today for the year ended December 31, 2021 (www.biolargo.com/sec-filings). Here, the company has provided highlights of its financial, commercial, and developmental advancements throughout the past year.

BioLargo will hold an investor webcast on Monday, April 4, 2022, at 1:30 pm Pacific / 4:30 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/44944

“The past year was pivotal for BioLargo,” said the company’s CEO, Dennis P. Calvert. “The credibility we have built as cleantech innovators, solution providers, and engineering project integrators has resulted in a steady increase in organic growth and enabled us to secure remarkable channel partners like Garratt-Callahan and Ikigai Marketing Works to promote accelerated growth. Our engineering division broke revenue records in both the third and fourth quarters of last year. And notably, our balance sheet continued to improve throughout 2021 while we continued to invest in the development and launch of our innovative technologies.”

He continued, “We are also working with a number of new industry champions and distributors that are just getting started representing our products and services and look forward to sharing more information about their progress in the future. We expect to make a big splash in the immediate future with our Aqueous Electrostatic Concentrator (AEC) PFAS treatment system, including with new channel partnerships, and we soon expect to secure our first commercial accounts with our Advanced Oxidation System (AOS) energy-efficient water treatment technology.”

Company management provides highlights of the annual report below, but encourages investors to review the full report to get the most complete information about BioLargo and its growing cleantech business.

Key financial highlights:

·         Consolidated revenue for the year ended December 31, 2021, was $2,531,000, which was a 4% increase over 2020. Revenue in the fourth quarter of 2021 was $784,000, a 10% quarter-over-quarter increase, and a decrease of 14% as compared with the fourth quarter of 2020.

·         The company continued its trend of reducing debt from its balance sheet. The company’s total debt, including that of its partially owned subsidiary Clyra Medical Technologies, was reduced from $2.9 million as of December 31, 2020, to $681,000 as of December 31, 2021, with the balance composed of obligations with favorable terms, including low-interest government loans.

·         The total net loss for the year was reduced by 29%, from $9.7 million to $6.9 million. This figure includes non-cash compensation expense related to options of $1.9 million and a non-cash impairment charge of $342,000. The company’s R&D investments continued and totalled $1.4 million for the year as it continued to advance and expand its technology portfolio.

·         Total liabilities were reduced by over $3 million, from $5.2 million to $2.1 million.

·         Expenses related to interest and extinguishment of debt were reduced by $2.2 million.

·         The company ended the year with $1.8 million in current assets, which included cash, accounts receivable, inventories and pre-paid expenses.

Key commercial and developmental highlights:

·         PFAS treatment technology: The BioLargo Aqueous Electrostatic Concentrator (AEC) was advanced significantly toward commercial readiness during 2021.The technology was used to treat PFAS-contaminated water provided by two prospective customers: a large municipality in Southern California, and a federal government agency. In both cases, the AEC was shown to eliminate (to a level of ‘non-detect’) a variety of PFAS compounds from the water, even in the presence of high salinity, which can often be a barrier for water treatment technologies. BioLargo management is confident that the results of these in-house studies will lead to in-field demonstration pilots, commercial trials, and commercial sales.

·         Garratt-Callahan partnership: BioLargo engineered and manufactured a commercial prototype of the “minimal liquid discharge” (MLD) water treatment system invented by North America’s largest privately held water treatment company, Garratt-Callahan. The MLD system passed its factory acceptance testing and was proven to remove over 98% of target contaminants from real wastewater provided by Garratt-Callahan customers. A commercial trailer-mounted unit is now being constructed and will be used for on-site demonstration with a Garratt-Callahan customer.

·         Ikigai partnership: BioLargo established a partnership with Ikigai Marketing Works, LLC to support the roll-out of a new pet odor control product based on BioLargo’s proprietary technology, ultimately aimed at adoption by big-box retailers. Ikigai completed a test-marketing phase to assess the likelihood that the new brand would be a commercial success and subsequently made orders for product (manufactured by BioLargo) that exceed both partners’ initial projections. BioLargo also earns a royalty on each bottle sold and would receive 20% of any eventual sale of the product line. Ikigai’s sales are growing.

·         ONM Environmental: ONM Environmental continues to focus on sales and develop channel partners to help sell its odor and VOC control product, air quality control systems, and associated services. The company has made headway with successful commercial trials and new accounts including in pulp and paper, wastewater, oil and gas, construction, and auto manufacturing. This business unit is expected to report record sales in Q1 2022 and a number of new distributors and industry segments are showing good prospects for growth.

·         Clyra Medical Technologies: Clyra introduced its new product, Bioclynse, to the market, secured its first two hospital customers for the product, established a robust quality control system for FDA compliance, recruited a national director of sales, and is negotiating with three separate channel partners to form a commercial alliance.

·         Municipal wastewater AOS pilot results: The commercial-scale demonstration pilot for the AOS waste treatment system at a municipal wastewater treatment plant near Montreal, Quebec, produced data that cements its value proposition as an energy-efficient treatment solution that tackles hard-to-treat contaminants. The pilot showed the AOS operates faster and uses less electricity than existing technologies while also disinfecting the wastewater, making it an efficient and uniquely flexible treatment option for hard-to-treat contaminants like pharmaceutical by-products. Recently, an NSERC grant has extended the project to allow for use of a higher flow-rate AOS system, as well as removal of PFAS chemicals through the installation of a pilot AEC system.

Mr. Calvert added, “There are a number of substantial new commercial projects in various stages of negotiation that have the potential to dwarf our existing project backlog. If these move forward as expected, we believe we will experience dramatic growth as these projects continue to advance to formal contracts, our channel partnerships continue to find market traction, and our reputation for quality work continues to expand.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Friday, 18 February 2022

BioLargo says current projects are “major growth catalysts,” as it shares updates with investors

 

Source: Proactive Investors (https://ca.proactiveinvestors.com/companies/news/974546/biolargo-says-current-projects-are-major-growth-catalysts-as-it-shares-updates-with-investors-974546.html

BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert joined Proactive's Stephen Gunnion with update on three key projects that he says are major growth catalysts for the company.

Calvert telling Proactive that BioLargo's disruptive solutions have the potential to build significant value for the company and its shareholders, resulting in increased attention from the market.

Thursday, 17 February 2022

BioLargo Provides Progress Report on Major Growth Catalysts

Westminster, CA – February 17, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, today provided an update on the progress of three important catalysts for commercial growth. 

“These initiatives are still unfolding, and in some cases, such as with PFAS testing on behalf of clients, we have to handle confidential information carefully,” said Dennis P. Calvert, President and CEO of BioLargo. “Still, we believe it’s important for our investors and followers to stay abreast of the progress of these projects that represent the key growth catalysts for our company.”

1) Garratt-Callahan / BioLargo Minimal Liquid Discharge Water Treatment System passes “factory acceptance testing”

A commercial prototype of the new “minimal liquid discharge” water treatment system, invented by North America’s largest privately held water treatment company, Garratt-Callahan, and engineered and built by BioLargo, passed the “factory acceptance” testing this week conducted by both BioLargo and Garratt-Callahan engineers at BioLargo’s Oak Ridge, Tennessee facility. The new water treatment system is designed to reuse and recycle, rather than discharge, treated wastewater, resulting in lower operational costs and less environmental impact for customers.

At this week’s performance testing, the system removed over 98% of the target contaminants from water provided by a Garratt-Callahan client in continuous operation, in line with results achieved by Garratt-Callahan’s original bench-scale and batch processing tests. This factory acceptance testing was a necessary step before commercial trials with Garratt-Callahan customers can begin. The first customer has already been identified, and the first on-site field trial for that customer is currently being planned.

Kelle Zeiher, Technical Project Manager at Garratt-Callahan, commented, “I’m excited about helping our customers move from water discharge to water reuse. This technology represents a dramatic, game-changing shift in how we manage industrial water for a more sustainable future.”

2) PFAS treatment solution 

Commercialization of BioLargo’s revolutionary PFAS removal system, the “Aqueous Electrostatic Concentrator”, or AEC, is progressing. While the company can’t give details on confidential client communications, nor reveal details of new innovations, it has recently completed a series of further studies with a potential client’s water to optimize technical and economic metrics and simulate the real-world conditions of a commercial trial. BioLargo’s engineers are currently preparing a final techno-economic case study report for the client that will be integral for establishing in-field trials at the client’s facilities, as well as at other prospective customers’ sites.

Additionally, BioLargo engineers recently completed in-house testing of the AEC using PFAS-contaminated water provided by BioLargo’s a federal government agency. While internal preliminary testing shows the AEC eliminated PFAS from the water stream, the treated water samples have been submitted to the University of Tennessee for determinative analysis.

On the commercial side, BioLargo is in discussions with both prospective customers and potential channel partners to develop and support sales and distribution of the AEC. 

3) Pet odor control product

As previously disclosed, BioLargo and its strategic partner, Ikigai Marketing Works, LLC, are working together to support Ikigai’s roll-out of a new pet odor control product based on BioLargo's proprietary technology. They have completed test marketing and their product orders from BioLargo thus far have exceeded the company’s expectations. Ikigai is comprised of veteran consumer product executives with experience launching and growing multiple blockbuster consumer products. Both BioLargo and Ikigai are excited about the opportunities ahead for this and potentially other pet-oriented products. 

BioLargo CEO Dennis Calvert commented, “We are making steady progress towards commercialization of our water treatment systems and have the benefit of working with experienced channel partners to get there. We’re also highly encouraged by the performance of the pet odor product being rolled out by partners at Ikigai. To say the team at BioLargo is excited would be an understatement.” 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com

Contact Information

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.


Thursday, 3 February 2022

BioLargo, Inc. Discusses Progress of Key Partnerships and its PFAS Treatment Technology with The Stock Day Podcast


Phoenix, Arizona--(Newsfile Corp. - February 3, 2022) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), a company that invents, develops, and commercializes innovative platform technologies that solve challenging environmental problems like PFAS contamination, advanced water treatment, and industrial odor and VOC control. BioLargo President and CEO Dennis P. Calvert joined Stock Day host Everett Jolly.
"What makes BioLargo unique in the clean technology and environmental space?" asked Jolly to start the interview. "It's all about sustainable environmental solutions, and we like to focus on big problems with huge markets," Calvert explained. "Commercial opportunities are expanding quickly, so we're really facing an extraordinary growth opportunity."
Jolly then asked about BioLargo's recent partnerships and their significance. Calvert explained that once their innovative technologies were developed, partnerships are necessary to achieve meaningful commercialization. "Once you're there, you partner your way to success," said Calvert.
Calvert expanded by using their partnership with Garratt-Callahan as an example. "Garratt-Callahan is the largest privately-held water [treatment] company in North America," he said. Our companies have been working together on a new 'minimal liquid discharge' product for industrial facilities. "The goal for that partnership is to sell about 30 to 50 units [in the first year that it launches]."
Calvert went on to talk about Ikigai Holdings, LLC, with whom BioLargo has partnered to launch a pet odor control product into the consumer market. "Ikigai is composed of experts in the brand-building business [who have] launched numerous products over their careers," he said. "Backed with venture capital, [they are] focused on the idea of exploiting their special talent, which is building brands, and they selected our pet odor control product as a platform on which to build their business."
"They have a big vision of a billion dollar per year brand," he continued. "We make a manufacturer's margin, as well as a 6% royalty on the technology, and 20% of the exit," said Calvert. "This is a great deal."
Jolly then asked Calvert about their technology that removes per- and polyfluoroalkyl substances (PFAS), also known as toxic 'forever chemicals', from water. "Our solution [the BioLargo AEC] is a low cost, low environmental impact solution," said Calvert. "These [PFAS] chemicals have been linked to adverse health effects," he explained. "It accumulates in your body, in the earth, it is everywhere." He then explained that the AEC's most important advantage over competing technologies is that it produces less than 1/1000 the PFAS-laden solid waste product compared to competitors while remaining economical and effective.
"Who are you targeting?" asked Jolly. "We are working with one of the largest municipal water districts in the industry," said Calvert. "We are doing work with supply chain partners that serve military bases," he added. "We are also working in the early stages with the mining field," said Calvert, adding that the company is working on developing commercial trials in each of those markets.
"Do you think this is a good time for companies to get involved with environmental technology companies like BioLargo?" asked Jolly. "The world is becoming smarter and smarter about the danger of these pollutants," said Calvert. "We have great technology and people that make it work, and we love our customers."
To close the interview, Calvert discussed the significance of BioLargo's potential as they continue to experience growth within the clean technology space and bring their environmental solutions to market.
Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/.

About BioLargo, Inc.
BioLargo, Inc. (OTCQB: BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

About The "Stock Day" Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:
Stock Day Media
(602) 821-1102

Tuesday, 25 January 2022

BioLargo PFAS treatment system highlighted in EPA report

BioLargo's innovative treatment system that removes per- and polyfluoroalkyl substances (PFAS) from water effectively and affordably has been highlighted as an emerging PFAS treatment technology in a new report from the EPA.

Link to the report here: https://www.epa.gov/system/files/documents/2021-09/multi-industry-pfas-study_preliminary-2021-report_508_2021.09.08.pdf





Monday, 24 January 2022

BioLargo AEC Featured in Treatment Plant Operator Magazine

BioLargo’s Aqueous Electrostatic Concentrator, the company’s treatment solution to effectively and affordably remove per- and polyfluoroalkyl substances from water, has been featured in a prominent water treatment industry publication, Treatment Plant Operator (TPO).

The article, which features an interview with BioLargo CEO Dennis Calvert and Director of Strategic Marketing and Business Development Tonya Chandler, does a deep dive on why the AEC is set to disrupt the PFAS treatment market.

Download your copy of the article here:

TPO0222 Technology Deep Dive